FDA’s Evolving Pipeline of iPSC and MSC Products

Reviewed by Dr. Ankeet Choxi

Summary: The FDA’s growing list of cleared iPSC- and MSC-based therapies signals increasing regulatory maturity for regenerative medicine. This article explores the evolving approval landscape, translational trends, and the clinical relevance of cell-based products – including progenitor cells, potency testing, and investigational trial pathways – shaping the future of biologic therapy.

Cell-Based Therapies in a Regulatory Renaissance

Regenerative medicine is reaching a turning point. Once dominated by experimental applications and unclear regulatory paths, today’s landscape is increasingly defined by FDA-approved cellular products, formal trial pipelines, and high-quality manufacturing standards. Leading the charge are therapies based on induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs).

With dozens of cell-based therapeutics now FDA-cleared for clinical use – including Ryoncil, Allocord, MACI, and Omnisirge – the field is transitioning from promise to practice. At the heart of this shift is the FDA’s effort to define translational pathways through clearer guidance, product classification, and commercialization benchmarks.

Understanding iPSC and MSC Therapies

iPSCs: Versatile and Engineered for Specific Lineages

Induced pluripotent stem cells (iPSCs) are adult cells genetically reprogrammed to behave like embryonic stem cells. They can be differentiated into specific progenitor cells such as:

• Retinal pigment epithelial cells
  
• Cardiomyocytes
  
• Neural and glial lineages
  
• Musculoskeletal precursors
  

This technology underpins several advanced therapies in development, offering personalized treatment potential with reduced ethical concerns.

MSCs: Multipotent, Immunomodulatory, and Prolific in Orthopedic Use

Mesenchymal stem cells (MSCs), commonly harvested from bone marrow, adipose tissue, or umbilical cords, have long been valued for their ability to:

• Support tissue regeneration
  
• Modulate immune response
  
• Home to injured or inflamed tissue
  

Unlike iPSCs, MSCs are typically used in an undifferentiated state and are favored for orthopedic, autoimmune, and inflammatory disorders.

Key FDA-Approved iPSC and MSC Products

Here are examples of cleared or regulated products based on or involving iPSC and MSC technologies, taken from your list:

MSC-Based or Related

• RYONCIL(remestemcel-L-rknd) by Mesoblast
  
  • Pediatric graft-versus-host disease (GVHD)
    
  • Allogeneic MSC product
    
• MACI(Autologous Cultured Chondrocytes on Porcine Collagen Membrane) by Vericel
  
  • Articular cartilage injuries in the knee
    
• OMISIRGE(omidubicel-onlv) by Gamida Cell
  
  • Cord blood-derived, stem cell-based therapy for hematologic disorders
    
• HEMACORD, ALLOCORD, and others
  
  • Umbilical cord blood products regulated under the HPC classification
    

Related iPSC Technologies or Advanced Cell Engineering

While few iPSC-derived products have yet received full FDA approval, multiple products involve cell reprogramming or are being developed using iPSC-based platforms, particularly in neurology, oncology, and gene therapy. For example:

• ZEVASKYN, ZYNTEGLO, and SKYSONA involve gene-edited autologous cell therapies, often intersecting with pluripotent cell lines.
  
• Early-phase IND trials for iPSC-derived retinal or cardiomyocyte cells are underway in academic and industry settings.
  

Trends in IND Submissions and FDA Guidance

The Center for Biologics Evaluation and Research (CBER) has taken steps to streamline the cell-based product pipeline:

• Regenerative Medicine Advanced Therapy (RMAT) designation offers fast-track development for products showing early clinical promise.
  
• FDA’s Guidance for Industry documents – especially on potency tests, donor eligibility, and minimal manipulation – have helped sponsors structure trials that meet regulatory expectations.
  

According to recent FDA briefings:

• IND submissions for MSC-based therapies continue to rise, especially in orthopedics, cardiovascular disease, and autoimmune conditions.
  
• iPSC-derived therapies are gaining interest, particularly for neurodegenerative and retinal disorders.
  

Manufacturing and Potency Testing Standards

Both iPSC and MSC products must comply with stringent FDA standards regarding:

1. Identity and Characterization

• Cell surface marker profiling
  
• Histological or genetic confirmation of identity
  

2. Potency Assays

• In vitro or in vivo models must demonstrate expected biological activity
  
• This includes cell viability, differentiation potential, and cytokine signaling
  

3. Safety and Purity

• Testing for microbial contamination, endotoxins, and residual reagents
  
• Tumorigenicity and genetic stability are especially critical in iPSC-derived lines
  

4. Sterility and GMP

• All clinical-grade products must be manufactured in GMP-compliant environments, using well-documented standard operating procedures (SOPs)
  

Commercialization and Clinical Expansion

As the FDA continues to refine pathways for regenerative biologics, several trends suggest expanding opportunity:

• Off-the-shelf allogeneic products like Ryoncil could become more common, offering scale and accessibility
  
• Combination products, pairing biologics with scaffolds or devices, are gaining traction in orthopedics (e.g., MACI)
  
• Decentralized trial networks are improving access to investigational therapies outside of major academic centers
  

For patients and providers alike, this growth signals a more accessible and evidence-driven era of regenerative medicine – with iPSC and MSC therapies playing central roles.

Read more at https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products.

FAQs

What’s the difference between iPSC and MSC therapies?
iPSCs can become almost any cell type and are often used in targeted cell replacement strategies. MSCs are multipotent and valued for immunomodulation and repair, especially in orthopedic and inflammatory conditions.

Are any iPSC-based therapies FDA-approved?
While some iPSC-derived therapies are in late-stage trials, most cleared therapies involve MSCs or related cell platforms. iPSC use remains more common in experimental and academic settings but is progressing rapidly.

What does RMAT designation mean?
Regenerative Medicine Advanced Therapy (RMAT) status helps expedite the development and review of promising cell-based treatments. It is granted by the FDA based on early clinical data.

How are these therapies manufactured safely?
FDA guidance requires GMP-compliant labs, validated potency and safety assays, and strict donor screening protocols to ensure product purity and performance.

What are the top use cases for MSC therapies today?
MSCs are most commonly used in orthopedic applications (cartilage repair, joint pain), GVHD, and inflammatory conditions, with increasing use in autoimmune and cardiovascular settings.

Disclaimer: The information provided in this article is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.

Certain regenerative medicine procedures discussed – such as stem cell therapy, exosome therapy, or other biologic treatments – may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.

Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.

© STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.